Pranshu Mohindra, Md, Mbbs
University of Maryland Medical Center
United States of America
Soon after completion of a second residency in radiation oncology in the U.S. (previously board certified in radiation oncology from the prestigious Tata Memorial Center, University of Mumbai, India in India and fellowship trained for head-neck cancer radiation oncology at the Princess Margaret Hospital, University of Toronto, Canada), Dr. Mohindra joined the Department of Radiation Oncology at the University of Maryland School of Medicine, Baltimore in July 2014 as an assistant professor in a clinician-scientist role. His primary area of clinical and research interest is in thoracic/lung, gynecological and hemato-lymphoid malignancies. Dr. Mohindra has received several academic excellence, research and travel awards during his residency including the 2014 Radiological Society of North America (RSNA) Roentgen Resident/Fellow Award for outstanding radiologic research and the 2014 American Society for Radiation Oncology (ASTRO) Resident Digital Poster Discussion Award in the Biology category. He also served as the Chief resident for the year 2013-14. Dr. Mohindra has active involvement in multi-disciplinary collaborative research endeavors including prospective clinical protocols with special emphasis on early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques. He currently serve as national PI of two NCI-sponsored phase-I clinical trials; one of which was career development project team award evaluating a novel DNA repair pathway inhibitor with whole brain radiotherapy (WBRT) in patients with brain metastases from NSCLC (CIRB and CTEP approved, NCT02589522). The other phase-I clinical trial evaluating combination of oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) with WBRT in brain metastases (CTEP approved, CIRB review pending). He is also a co-PI for an ongoing phase Ia-b dose escalation study evaluating the safety and efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) with concomitant capecitabine for resectable pancreatic carcinoma (NCT01918644) and a co-investigator on an ongoing phase II clinical study evaluating the role of pulsed-reduced dose-rate (PRDR) radiation therapy with bevacizumab for recurrent highgrade gliomas (University of Wisconsin Hospital and Clinics, NCT01743950). He was also recently appointed as national Radiation Oncology Co-Chair on an Alliance for Clinical Trials in Oncology Clinical trial (ALLIANCE A041501) that is currently under development. Dr. Mohindra is an appointed member of the ACR Radiation Oncology In-Training (TXITTM) Exam committee developing examination questions for residents in radiation oncology. He served as an appointed member of committees within the American Society for Radiation Oncology (ASTRO) and Alliance for Clinical Trials in Oncology.
Thoracic/lung cancers, gynecological malignancies, hemato-lymphoid malignancies, intensity modulated proton therapy (IMPT)/pencil beam scanning proton therapy, intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), Image-guided Brachytherapy.
de Faria EB, Barrow KR, Ruehle BT, Parker JT, Swartz E, Taylor-Howell C, Kieta KM, Lees CJ, Sleeper MM, Dobbin T, Baron AD, Mohindra P, MacVittie TJ. The Evolving Mcart Multimodal Imaging Core: Establishing a Protocol for Computed Tomography and Echocardiography in the Rhesus Macaque to Perform Longitudinal Analysis of Radiation-Induced Organ Injury. Health Phys. 2015 Nov;109(5):479-92. PMID: 26425907.
Murigi FN, Mohindra P, Hung C, Salimi S, Goetz W, Pavlovic R, Jackson IL, Vujaskovic Z. Dose Optimization Study of AEOL 10150 as a Mitigator of Radiation-Induced Lung Injury in CBA/J Mice. Radiat Res. 2015 Oct;184(4):422-32. Epub 2015 Sep 28. PMID: 26414508
Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM.Dose Limiting Toxicity Following Hypofractionated Dose-Escalated Radiotherapy In Non-Small Cell Lung Cancer. JCO 2013 Oct. 21 [Epub ahead of print]. PMID: 24145340